Bluejay Therapeutics
Sue Naim is a seasoned professional in clinical operations and outsourcing, currently serving as the Senior Vice President of Clinical Operations and Clinical Outsourcing at Bluejay Therapeutics since March 2025. With a robust background in the biopharmaceutical industry, Naim previously held the role of Senior Vice President at ALX Oncology from July 2020 to March 2025, as well as leadership positions at Astex Pharmaceuticals, Metabolex, Cell Genesys, Mentor, and ICN Pharmaceuticals. Naim's experience encompasses site management, contract negotiation, and collaboration with regulatory teams, and includes a strong foundation in clinical trial support. Naim's academic background includes a degree from UCLA.
This person is not in any teams
This person is not in any offices
Bluejay Therapeutics
Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.